Progenics Pharmaceuticals, Inc.
(NASDAQ GS: PGNX)
Attention investors who purchased shares of Progenics Pharmaceuticals, Inc. before October 2, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of Progenics Pharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to merge with Lantheus Holdings, Inc.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ GS: PGNX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ GS: LNTH). Under the terms of the agreement, shareholders of Progenics will receive 0.2502 of a share of Lantheus common stock for each share of Progenics they own. Upon closing, Progenics shareholders will own approximately 35% of the combined company.
If you own common stock of Progenics and purchased any shares before October 2, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.